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Renal ischemia and reperfusion (I/R) is the major cause of acute kidney injury in hospitalized patients. Mechanisms underlying
reperfusion-associated injury include recruitment and activation of leukocytes and release of inflammatory mediators. In this
study, we investigated the renal effects of acute administration of AVE0991, an agonist of Mas, the angiotensin-(1–7) receptor, the
angiotensin-(1–7) receptor, in a murine model of renal I/R. Male C57BL/6 wild-type or Mas−/− mice were subjected to 30min of
bilateral ischemia and 24 h of reperfusion. Administration of AVE0991 promoted renoprotective effects, as seen by improvement of
function, decreased tissue injury, prevention of local and remote leucocyte infiltration, and release of the chemokine, CXCL1. I/R
injury was similar in WT and Mas−/− mice, suggesting that endogenous activation of this receptor does not control renal damage
under baseline conditions. In conclusion, pharmacological interventions using Mas receptor agonists may represent a therapeutic
opportunity for the treatment of renal I/R injury.
1. Introduction
Acute kidney injury (AKI) is defined as a rapid decrease of
the glomerular filtration rate that occurs in minutes or days.
Renal ischemia and reperfusion (I/R) is a major cause of AKI
in hospitalized patients [1–3]. Renal I/R triggers an inflam-
matory cascade clearly involved in the pathogenesis of AKI
[4–6]. The control of inflammatory responses emerges as a
putative therapeutic target to halt AKI [7]. Many regulatory
systems modulate inflammation in renal tissue [4]. Among
these systems, the Renin Angiotensin System (RAS) seems to
exert a pivotal action in this scenario [8]. RAS is now regard-
ed as a dual system with two opposite arms: the classical one
formed by angiotensin converting enzyme (ACE), Angiot-
ensin II (Ang II), and receptor type 1 (AT1) and the counter-
regulatory arm comprising the enzyme ACE2, Angiotensin-
(1–7) [Ang-(1–7)], and Mas receptor [9–13].
Besides opposing AT1 receptor [14], the activation of
Mas receptor by Ang-(1–7) or Ang-(1–7) agonists elicits
renal effects [15–18]. Concerning experimental AKI, our
team has recently shown that renal levels of Ang-(1–7)
and ACE2 were significantly reduced whereas Mas receptor
expression was increased [19]. However, our study was not
able to clarify the precise function of the RAS at the early
stages of renal I/R. In addition, data on the endogenous
relevance of Mas receptor activation in renal tissue are still
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controversial [20, 21]. While Pinheiro et al. [20] showed that
the genetic deletion of Mas receptor in C57Bl/6 mice led
to glomerular hyperfiltration, proteinuria, and renal fibrosis,
Esteban et al. [21] reported, otherwise, that renal deficiency
of Mas diminished renal damage in unilateral ureteral
obstruction and in I/R. Infusion of Ang-(1–7) to wild-type
mice appeared to worsen the inflammatory response [21].
More recently, we have shown that administration of
Ang-(1–7) or the orally active agonist, the non-peptide
compound AVE0991, exerted anti-inflammatory effects in
experimental models of arthritis [19] and of nephritic
syndrome [22]. Therefore, the purpose of the present study
was to evaluate the renal effects of AVE0991 administration
in a mice model of AKI, induced by renal ischemia following
reperfusion.
2. Materials andMethods
2.1. Animals. Eight- to 10-week-old C57BL/6 wild-type
male mice (Mas+/+) weighing 20–25 g or mice with genetic
deletion of Mas receptor (Mas−/−) were obtained from the
animal facility of the Universidade Federal de Minas Gerais.
Animals were maintained under temperature-controlled
conditions with an artificial 12-h light/dark cycle and were
allowed standard chow and water ad libitum. The study was
approved by the Ethics Committee of our Institution.
2.2. Renal Ischemia/Reperfusion Injury (I/R). Mice were an-
esthetized with ketamine and xylazine (150mg/kg and
10mg/kg, resp.). Abdominal incision was performed to
expose both renal pedicles. Ischemia was induced by totally
occluding the renal pedicle for 30 minutes, using micro-
surgical clamps. After inspection for signs of ischemia,
the wound was covered with cotton soaked with sterile
PBS. After 30min, clamps were released and blood-flow
was reestablished, as confirmed by visual inspection of
the kidneys. The wound was sutured in two layers using
5.0 sutures (Procare, Brazil). Throughout the experiments,
body temperature was kept at 36–38◦C by placing mice
on a heating pad. Sham-operated animals were used as
controls in all experimental protocols. These animals were
also anesthetized and subjected to abdominal incision,
exposing, and superficial manipulation of the renal pedicles.
After recovery from anesthesia, mice were accommodated in
individual metabolic cages (Tecniplast, Italy) for evaluation
of renal function parameters. Urine was collected for the
first 24 h after which mice were killed. Samples of plasma,
renal, and lung tissues were collected and stored at −20◦C
for posterior analysis.
2.3. Study Protocol. The first set of experiments was to
evaluate the effect of AVE0991 treatment in renal I/R
injury. Therefore, wild type (Mas+/+) mice submitted to I/R
were treated with subcutaneous (sc) injection (200 μL) of
AVE0991 (9.0mg/kg) (Aventis Pharma Deutschland, Frank-
furt, Germany), AVE group; or vehicle (10mMKOH in 0.9%
NaCl), VE group, immediately following 30 minutes of the
renal ischemia and 12 h after renal reperfusion (AVE group)
or vehicle (VE group). As control group, sham-operated
Mas+/+ mice were also treated with vehicle (CT group).
The second set of the experiments had the aim to verify
the endogenous role of Mas receptor in modulating experi-
mental AKI. Thus, mice with genetic deletion ofMas receptor
were submitted to the same protocol of renal I/R.
2.4. Determination of the MPO Activity. The extent of
neutrophil accumulation in the kidney and lung tissue
was measured by assaying myeloperoxidase (MPO) activity,
as described previously [22]. Briefly, a portion of the
kidney or lungs was removed and frozen in liquid nitrogen,
homogenates were prepared in 1mL of PBS containing
0.5% hexadecyltrimethyl ammonium bromide (HTAB) and
5mM EDTA using a Dispomix tissue homogenizer (Medic
Tools), and the protocol was followed as already described.
Neutrophil number in each sample was calculated from a
standard curve obtained from the peritoneal cavity after
stimulation with 5% casein. The results were expressed as
relative unit.
2.5. Differential Blood Cell Count. The total number of
leukocytes was counted in a Neubauer chamber after staining
with Turk’s solution, and differential leukocyte counts were
obtained after staining with May-Grunwald-Giemsa using
standard morphologic criteria.
2.6. Assessment of CXCL1 in Serum. Levels of the chemokine
CXCL1/KC were measured in serum using a commercial
available enzyme-linked immunosorbent assay (ELISA) in
accordance with the procedures supplied by the manu-
facturer (R&D Systems, Minneapolis, MN), as previously
described by Souza et al. [14]. Results were expressed as
picograms of cytokine per mL of serum.
2.7. Renal Function. To evaluate the effects of renal ischemia
and reperfusion, as well as of the treatment with AVE0991
on renal physiology, several parameters were evaluated.
First, mice were housed individually in metabolic cages
(Tecniplast, Italy) three days before I/R procedure to adapt to
the cages. I/R was then performed and animals were placed
in the metabolic cages soon after recovering from anesthesia.
Groups of animals were killed 24 h after reperfusion.
At the end, 24 h urine samples were collected and
centrifuged at 3,000 g for 5min. Urine was used to determine
osmolality and creatinine concentrations. Blood samples
were collected from the lower abdominal cava vein, under
ketamine and xylazine anesthesia (150mg/kg and 10mg/kg,
resp.), and centrifuged at 2,000×g for 15min at 4◦C.
The resulting plasma was used to measure osmolality and
creatinine concentrations. Samples of urine and plasma were
stored at −20◦C until assessments.
Creatinine concentrations were determined using an en-
zymatic kit (Bioclin/Quibasa, Belo Horizonte, MG, Brazil),
and osmolality was determined by a freezing-point osmome-
ter (microOsmetter, Calumet City, IL, USA). Osmolar clear-
ance and free-water clearance were calculated. Finally, body
weights were recorded daily.
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Table 1: Effect of renal ischemia and reperfusion on renal function parameters, local CXCL1 production, and local and remote neutrophil
accumulation. Urinary creatinine (mg/dL), serum creatinine (mg/dL), serum osmolality (mOsm/Kg H2O), urinary osmolality (mOsm/Kg
H2O), serum CXCL1 (pl/mL serum), and renal and pulmonary neutrophils (relative units).
Control I/R n P
Urinary creatinine (mg/dL) 700± 5.1 170± 1.2∗ 6 0.001
Serum creatinine (mg/dL) 0.29± 0.1 5.34± 1.2∗ 4 0.016
Serum osmolality (mOsm/Kg H2O) 317± 10.4 360± 17.8∗ 6 0.006
Urinary osmolality (mOsm/Kg H2O) 3996± 340 905± 69∗ 6 0.06
Serum CXCL1/KC (pg/mL) 94± 70 940± 164∗ 6 0.008
Renal neutrophils (relative units) 0.26± 0.13 5.3± 1.2∗ 4 0.016
Lung neutrophils (relative Units) 2.2± 0.5 5.6± 0.5∗ 5 0.0015
2.8. Renal Histopathology. Paraffin-embedded sections
(4mm thick) were deparaffinized with xylene and rehydrated
through a descending ethanol gradient. Histological sections
were examined following H&E staining, and classified
according to published standards [15, 16]. The degree
of segmental glomerulosclerosis (glomerulosclerosis and
nephron damage) was assessed by computer-aided image
analysis of H&E-stained kidney sections. A semiquantitative
score (glomerular and tubular injury index) was used
to evaluate the degree of scarring as previously described
[15, 16]. All scoring was performed in a blinded manner. The
damage was scored semiquantitatively on a scale of 1 to 5.
2.9. Statistical Analysis. All results are presented as the mean
± SEM. Normalized data were analyzed by one-way ANOVA,
and differences between groups were assessed using Student-
Newman-Keuls post-test. The level of significance was set at
P < 0.05.
3. Results and Discussion
It is well known that the classical RAS axis, composed of
ACE/Ang II/AT1 receptor, plays a role in mediating AKI [17,
18, 23]. Recently, studies have also demonstrated an impor-
tant role of the counterregulatory RAS axis, ACE2/Ang-
(1–7)/Mas receptor, in several renal disorders, including
AKI [19, 21, 24–28]. However, there are inconsistencies on
the role of Mas receptor activation in renal disorders [20,
21]. As example, Pinheiro et al. [20] showed that genetic
deletion of Mas receptor in C57BL/6 mice led to glomerular
hyperfiltration, proteinuria, and renal fibrosis. In contrast,
Esteban et al. [21] reported that renal deficiency for Mas
diminished renal damage in unilateral ureteral obstruction
and ischemia/reperfusion injury and the infusion of Ang-(1–
7) to wild-type mice elicited inflammatory response. There-
fore, whether the actions of Ang-(1–7) on renal function do
indeed counter act those of Ang II in the context of disease
states remains to be shown [20, 21]. In the present study,
we investigated the renal effects of acute administration of
the Mas receptor agonist, AVE0991, in a murine model of
AKI caused by reperfusion of ischemic kidneys. Our major
findings can be summarized as follows: (1) treatment with
AVE0991 improves renal function and attenuates renal tissue
damage; (2) the compound reduces infiltration of leukocytes
in the kidney and overall tissue inflammation. On the other
hand, despite the effectiveness the agonist of Mas receptor,
AVE0991, in protecting the kidney against I/R injury, the
same degree of renal damage was obtained in Mas−/− mice
submitted to experimental AKI. This finding suggests that
there is no protective role for endogenous Mas activation.
3.1. Renal Function and Inflammatory Parameters. As dis-
played in Table 1, bilateral ischemia (30 minutes) followed
by reperfusion (24 h) causes an acute decrease of glomerular
filtration characterized by the accumulation of serum cre-
atinine (Table 1). Serum and urinary osmolality were also
altered by I/R injury. The osmolality was elevated in the
serum and reduced in the urine of mice submitted to I/R
in comparison to sham-operated animals. The increase in
serum osmolality can be attributable to the failure of the
injured kidney to excrete nitrogen waste products and other
osmotic active molecules, while the reduction in urinary
osmolality probably reflects the loss of urinary concentration
ability by ischemic renal tubules. Taken together, these
functional data confirm the acute and significant impairment
in renal function as a result of I/R injury [1, 2].
I/R of the kidney is followed by a robust inflammatory
reaction in the renal tubulointerstitium [29]. Studies in
rodents have suggested that many components of the innate
immune system contribute to renal injury after I/R, including
neutrophils [30] and monocytes [31, 32]. Inflammatory
cytokines and chemokines are generated in the ischemic
kidney [30, 33] and likely orchestrate this broad inflamma-
tory response. CXCL1/KC is a chemokine that promotes the
recruitment and activation of inflammatory cells into renal
tissue during I/R process [7]. In addition to renal damage,
it was previously shown that extensive I/R, such as that of
the renal or intestinal vascular beds, may be accompanied
by remote organ (lung) and systemic inflammation [34,
35]. In the present study, we demonstrated an important
increase in renal CXCL1/KC levels (Table 1). There was an
increase in systemic and local (in renal tissue) accumulation
of neutrophils, as detected by myeloperoxidade assay, which
is in agreement with other studies [31, 35]. Pulskens et al.
[36] and Roelofs et al. [37] found that neutrophils are the
first inflammatory cells infiltrating the damaged kidney after
reperfusion injury and there is much evidence suggesting
that neutrophils are crucial for the development of reperfu-
sion injury [37–39].
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Figure 1: Effects of the treatment with AVE0991 in a model of renal ischemia and reperfusion in mice. AVE0991 (AVE, 9.0mg/kg) or vehicle
(VE; 10mMKOH in 0.9% NaCl) was given immediately after ischemia and 12 h after reperfusion. All analyses were performed at 24 h after
reperfusion. Serum creatinine (a), number of neutrophils in blood (b), levels of CXCL1/KC (c), and relative number of neutrophils in renal
tissue (d) are shown as the mean ± SEM from six mice per group. ∗P < 0.05 when compared with VE-treated animals; #P < 0.05 when
compared with sham-operated animals (CT, control).
3.2. Effect of the Mas Receptor Agonist, AVE0991, in Renal I/R.
Recent studies have evidenced a renoprotective and anti-
inflammatory effect of ACE2/Ang-(1–7)/Mas receptor axis
activation in the context of numerous disease models [26,
40]. These findings encouraged us to investigate the effect
of an agonist of Mas receptor, AVE0991, in experimental
AKI. The elevation of serum creatinine is one of the most
important biomarkers of impaired glomerular filtration
present in AKI [41]. We demonstrated that AVE0991 was
able to attenuate the increase of serum creatinine, when
compared to the vehicle-treated group (Figure 1(a)).
There was a marked infiltration of neutrophils in renal
and pulmonary tissues after I/R injury (Figures 1(b)-1(c)).
Treatment with AVE0991 significantly decreased neutrophil
influx in both the kidney and lungs (Figures 1(b) and
1(c)). Decrease in neutrophil accumulation in both organs
was associated with reduced production of CXCL1/KC, as
seen by lower circulating levels of this chemokine in AVE-
treated animals than in vehicle group (Figure 1(d)). Systemic
and remote organ inflammation frequently accompanies
severe I/R injury [34, 42] and may contribute to the fatal
outcome observed in reperfused mice. The lung is the most
commonly affected remote organ during systemic inflamma-
tion [34, 35, 43, 44]. Therefore, protection against systemic
inflammation may have accounted for the overall beneficial
effects of AVE0991 treatment. We have recently shown that
Mas receptor activation decreased neutrophil migration and
accumulation in models of arthritis [45], suggesting the
overall capacity of Mas receptor activation in controlling the
influx of these cells during acute inflammatory response.
As an attempt to quantify the protective action of
AVE0991 at the level of the renal tissue, the degree of tubular
and glomerular injuries was evaluated in mice subjected to
I/R. As expected, sham-operated animals (control group)
had well-preserved glomerular and tubular architecture (Fig-
ures 2(a)-2(b)). Thirty minutes of ischemia followed by 24 h
of reperfusion caused focal acute tubular necrosis, intense
tubular vacuolization in proximal tubules (asterisks), cast
formation (arrows), and tubular dilatation as observed in
vehicle-treated animals submitted to I/R (Figures 2(c)-2(d)).
On the other hand, the administration of AVE0991 improved
renal damage in animals submitted to I/R (Figures 2(e)-2(f)).
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Figure 2: Effects of the treatment with AVE0991 in histological injury in a model of renal ischemia and reperfusion in mice. AVE0991 (AVE,
9.0mg/kg) or vehicle (VE; 10mMKOH in 0.9% NaCl) was given immediately after ischemia and 12 h after reperfusion. All analyses were
performed at 24 h after reperfusion. Representative photomicrographs show H&E-stained sections from sham-operated animals (CT, a, b)
and animals subjected to I/R, which were treated with vehicle (VE, c, d) and AVE0991 (AVE, 9mg/kg, e, f). There was severe renal damage
with vacuolization of tubular epithelium (c) (insert) and tubular dilation and protein casts (arrow) and extensive tubular necrosis (d) in
mice subjected to I/R. Original magnification: ×600. Index of glomerular injury (g) and index of tubulointerstitial injury (h) were graded
in a blind manner, as described in Material and Methods. Symbols represent results in single animals, and the trace is median value for all
animals. ∗P < 0.05 when compared with VE-treated group; #P < 0.05 when compared with CT.
The renal tissue of AVE-treated animals had a significant
decrease in the indexes of renal injury at both glomerular and
tubular sites when compared to vehicle group (Figure 2(h)).
Studies evaluating the effect of Ang-(1–7) or AVE0991
in models of chronic kidney disease have shown that these
molecules might be renoprotective [25, 26]. In this regard,
Zhang et al. showed that Ang-(1–7) infusion ameliorates
glomerular sclerosis in experimental glomerulonephritis
[24]. In addition, the beneficial effect of ACE2 overexpres-
sion in experimental diabetic nephropathy may also be due
to the increase of Ang-(1–7) levels [24]. These studies concur
with our findings that the agonist of Mas receptor, AVE0991,
attenuates renal damage in this model of I/R injury. Based
on our previous results with experimental arthritis [45], we
believe that AVE0991 exerted renoprotective actions mainly
through Mas receptor activation. To corroborate this idea,
our group has previous shown that the mRNA expression
for Mas receptor is increased in I/R model [19]. However,
we cannot rule out the possibility that other mechanisms
could contribute to the beneficial effects of AVE0991. In this
regard, AVE0991 could interact with ACE by inhibiting the
renal activity of this enzyme.
To verify the endogenous role of Mas receptor activation
in the pathogenesis of renal I/R, we induced AKI inmice with
genetic deletion of this receptor (Mas−/−). As demonstrated
in Figure 3, the absence of Mas receptor did not change the
degree of renal function impairment, as assessed by serum
creatinine concentration (Figure 3(a)). Moreover, there was
no change in inflammatory response, as measured by the
number of systemic and renal neutrophils (Figures 3(b)-
3(c)). The increase of Mas receptor could represent more
a compensatory response to renal damage rather than an
endogenous regulatory mechanism. In this regard, we have
previously obtained the same finding in a model of arthritis
induced by adjuvant [45]; that is, the phenotype of Mas-
deficient mice was not major when compared to phar-
macological administration of AVE0991, which were able
to efficiently control articular inflammation through Mas
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Figure 3: Ischemia and reperfusion in mice with genetic deletion for the Ang-(1–7) Mas receptor (Mas−/−) or WT mice (Mas +/+). Animals
were subjected to 30min of ischemia followed by 24 h of reperfusion. Serum creatinine (a), relative number of neutrophils in renal tissue
(b), and number of neutrophils in blood (c) are shown as the mean ± SEM of six mice per group.
receptor activation. Similarly, endogenous activation of Mas
receptor does not appear to exert a major role in I/R model.
The present results are in contrast to those of Esteban
et al. [21], which showed less intense reperfusion injury in
Mas−/− mice. These data are difficult to reconcile. However,
there are substantial differences between the experimental
protocols for producing I/R model and for the Mas receptor
agonist administration such as which agonist was admin-
istered, AVE0991 or Ang-(1–7), the via of administration,
and the dose used. For example, in the present study, we
have used a model of bilateral I/R (30min), while Esteban
et al. performed unilateral I/R (25min) with contralateral
nephrectomy [21] that could at least in part account for
the differences observed. Renal effects of Mas receptor
agonists, Ang-(1–7) and AVE0991, appear to be importantly
influenced by experimental conditions and the level of
RAS activation. Despite these inconsistencies, our results
corroborate emerging data showing that the major overall
effects of ACE2/Ang-(1–7)/Mas receptor axis stimulation
are anti-inflammatory [19, 21, 24–28]. As such, one would
expect that absence of this pathway would be associated with
no phenotype, as observed here, or even worsening of the
inflammatory response [37].
In conclusion, treatment with AVE0991, a nonpep-
tide Mas agonist, attenuated renal functional impairment,
decreased the local and systemic inflammatory responses,
and reduced glomerular and tubulointerstitial damage in
a murine model of AKI induced by bilateral I/R injury.
These results show that activation of Mas receptor is
renoprotective, at least in part by anti-inflammatory actions,
in mice subjected to AKI, a tenet that clearly deserves further
investigation in the context of human disease.
Acknowledgments
The paper received financial support from Coordenac¸a˜o de
Aperfeic¸oamento de Pessoal de Nı´vel Superior (CAPES),
Conselho Nacional de Desenvolvimento Cientı´fico e Tec-
nolo´gico (CNPq), and Fundac¸a˜o do Amparo a` Pesquisa do
Estado de Minas Gerais (FAPEMIG).
References
[1] M. Agrawal and R. Swartz, “Acute renal failure,” American
Family Physician, vol. 61, no. 7, pp. 2077–2088, 2000.
[2] J. G. Abuelo, “Normotensive ischemic acute renal failure,”New
England Journal of Medicine, vol. 357, no. 8, pp. 797–805, 2007.
[3] G. M. Chertow, E. Burdick, M. Honour, J. V. Bonventre, and
D.W. Bates, “Acute kidney injury, mortality, length of stay, and
costs in hospitalized patients,” Journal of the American Society
of Nephrology, vol. 16, no. 11, pp. 3365–3370, 2005.
[4] A. Karkar, “Cytokines and glomerulonephritis,” Saudi Journal
of Kidney Diseases and Transplantation, vol. 15, no. 4, pp. 473–
485, 2004.
[5] R. Thadhani, M. Pascual, and J. V. Bonventre, “Acute renal
failure,” New England Journal of Medicine, vol. 334, no. 22, pp.
1448–1460, 1996.
[6] H. R. Jang, G. J. Ko, B. A. Wasowska, and H. Rabb,
“The interaction between ischemia-reperfusion and immune
responses in the kidney,” Journal of Molecular Medicine, vol.
87, no. 9, pp. 859–864, 2009.
[7] I. Stroo, G. Stokman, G. J. D. Teske et al., “Chemokine expres-
sion in renal ischemia/reperfusion injury is most profound
during the reparative phase,” International Immunology, vol.
22, no. 6, pp. 433–442, 2010.
[8] A. Benigni, P. Cassis, and G. Remuzzi, “Angiotensin II
revisited: new roles in inflammation, immunology and aging,”
EMBO Molecular Medicine, vol. 2, no. 7, pp. 247–257, 2010.
[9] R. A. S. Santos, A. Ferreira, and A. S. E. Silva, “Angiotensins,”
in Cardiovascular Hormone Systems, W.-V. V. G Co, Ed., pp.
67–100, 2008.
[10] M. Iwai and M. Horiuchi, “Devil and angel in the renin-
angiotensin system: ACE-angiotensin II-AT1 receptor axis
vs. ACE2-angiotensin-(1–7)-Mas receptor axis,” Hypertension
Research, vol. 32, no. 7, pp. 533–536, 2009.
[11] M. C. Chappell, “Emerging evidence for a functional angi-
otensin-converting enzyme 2-angiotensin-(1–7)-Mas receptor
axis: more than regulation of blood pressure?” Hypertension,
vol. 50, no. 4, pp. 596–599, 2007.
[12] C. M. Ferrario, “ACE2: more of Ang-(1–7) or less Ang II?”
Current Opinion in Nephrology and Hypertension, vol. 20, no.
1, p. 6, 2011.
[13] R. A. S. Santos, A. J. Ferreira, and E. S. A. C. Simo˜es,
“Recent advances in the angiotensin-converting enzyme
International Journal of Hypertension 7
2-angiotensin(1–7)-Mas axis,” Experimental Physiology, vol.
93, no. 5, pp. 519–527, 2008.
[14] D. G. Souza, V. Pinho, A. C. Soares, T. Shimizu, S. Ishii,
and M. M. Teixeira, “Role of PAF receptors during intestinal
ischemia and reperfusion injury. A comparative study between
PAF receptor-deficient mice and PAF receptor antagonist
treatment,” British Journal of Pharmacology, vol. 139, no. 4, pp.
733–740, 2003.
[15] C. Zoja, D. Corna, D. Rottoli et al., “Effect of combining
ACE inhibitor and statin in severe experimental nephropathy,”
Kidney International, vol. 61, no. 5, pp. 1635–1645, 2002.
[16] S. C. Tang, J. C. K. Leung, L. Y. Y. Chan, A. A. Eddy, and
K. N. Lai, “Angiotensin converting enzyme inhibitor but not
angiotensin receptor blockade or statin ameliorates murine
adriamycin nephropathy,” Kidney International, vol. 73, no. 3,
pp. 288–299, 2008.
[17] B. A. Molitoris and T. A. Sutton, “Endothelial injury and
dysfunction: role in the extension phase of acute renal failure,”
Kidney International, vol. 66, no. 2, pp. 496–499, 2004.
[18] J. Kontogiannis and K. D. Burns, “Role of AT1 angiotensin
II receptors in renal ischemic injury,” American Journal of
Physiology, vol. 274, no. 1, part 2, pp. F79–F90, 1998.
[19] K. D. da Silveira, K. S. P. Bosco, L. R. L. Diniz et al., “ACE2-
angiotensin-(1–7)-Mas axis in renal ischaemia/reperfusion
injury in rats,” Clinical Science, vol. 119, no. 9, pp. 385–394,
2010.
[20] S. V. B. Pinheiro, A. J. Ferreira, G. T. Kitten et al., “Genetic
deletion of the angiotensin-(1–7) receptor Mas leads to
glomerular hyperfiltration and microalbuminuria,” Kidney
International, vol. 75, no. 11, pp. 1184–1193, 2009.
[21] V. Esteban, S. Heringer-Walther, A. Sterner-Kock et al.,
“Angiotensin-(1–7) and the G protein-coupled receptor Mas
are key players in renal inflammation,” PLoS ONE, vol. 4, no.
4, Article ID e5406, 2009.
[22] K. D. Silveira, F. M. Coelho, A. T. Vieira et al., “The ad-
ministration of the agonist of angiotensin-(1–7), AVE0991,
improved inflammation and proteinuria in experimental
nephrotic syndrome,” in Proceedings of the 15th Congress of
the International Pediatric Nephrology Association, vol. 25, pp.
1779–2004, Pediatric Nephrology, New York, NY, USA, 2010.
[23] F. E. Mackie, D. J. Campbell, and T. W. Meyer, “Intrarenal
angiotensin and bradykinin peptide levels in the remnant
kidney model of renal insufficiency,” Kidney International, vol.
59, no. 4, pp. 1458–1465, 2001.
[24] I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi,
and D. I. Diz, “Angiotensin-(1–7) prevents diabetes-induced
cardiovascular dysfunction,” American Journal of Physiology—
Heart and Circulatory Physiology, vol. 292, no. 1, pp. H666–
H672, 2007.
[25] C. X. Liu, Q. Hu, Y. Wang et al., “Angiotensin-converting
enzyme (ACE) 2 overexpression ameliorates glomerular injury
in a rat model of diabetic nephropathy: a comparison with
ACE inhibition,” Molecular Medicine, vol. 17, no. 1-2, pp. 59–
69, 2011.
[26] J. Zhang, N. A. Noble, W. A. Border, and Y. Huang,
“Infusion of angiotensin-(1–7) reduces glomerulosclero-
sis through counteracting angiotensin II in experimental
glomerulonephritis,” American Journal of Physiology—Renal
Physiology, vol. 298, no. 3, pp. F579–F588, 2010.
[27] A. Shiota, K. Yamamoto, M. Ohishi et al., “Loss of ACE2
accelerates time-dependent glomerular and tubulointerstitial
damage in streptozotocin-induced diabetic mice,” Hyperten-
sion Research, vol. 33, no. 4, pp. 298–307, 2010.
[28] W. C. Burns, E. Velkoska, R. Dean, L. M. Burrell, and M.
C. Thomas, “Angiotensin II mediates epithelial-to-mesenchy-
mal transformation in tubular cells by ANG 1-7/MAS-1-
dependent pathways,” American Journal of Physiology, vol. 299,
no. 3, pp. F585–F593, 2010.
[29] J. V. Bonventre and A. Zuk, “Ischemic acute renal failure: an
inflammatory disease?”Kidney International, vol. 66, no. 2, pp.
480–485, 2004.
[30] K. J. Kelly, W. W. Williams, R. B. Colvin et al., “Intercellular
adhesion molecule-1-deficient mice are protected against
ischemic renal injury,” Journal of Clinical Investigation, vol. 97,
no. 4, pp. 1056–1063, 1996.
[31] H. T. Lee, S.W. Park, M. Kim, and V. D. D’Agati, “Acute kidney
injury after hepatic ischemia and reperfusion injury in mice,”
Laboratory Investigation, vol. 89, no. 2, pp. 196–208, 2009.
[32] K. E. de Greef, D. K. Ysebaert, S. Dauwe et al., “Anti-
B7-1 blocks mononuclear cell adherence in vasa recta after
ischemia,” Kidney International, vol. 60, no. 4, pp. 1415–1427,
2001.
[33] R. R. Molls, V. Savransky, M. Liu et al., “Keratinocyte-derived
chemokine is an early biomarker of ischemic acute kidney
injury,” American Journal of Physiology, vol. 290, no. 5, pp.
F1187–F1193, 2006.
[34] D. G. Souza, D. C. Cara, G. D. Cassali et al., “Effects of the PAF
receptor antagonist UK74505 on local and remote reperfusion
injuries following ischaemia of the superior mesenteric artery
in the rat,” British Journal of Pharmacology, vol. 131, no. 8, pp.
1800–1808, 2000.
[35] K. Pompermayer, D. G. Souza, G. G. Lara et al., “The ATP-
sensitive potassium channel blocker glibenclamide prevents
renal ischemia/reperfusion injury in rats,” Kidney Interna-
tional, vol. 67, no. 5, pp. 1785–1796, 2005.
[36] W. P. Pulskens, G. J. Teske, L. M. Butter et al., “Toll-like
receptor-4 coordinates the innate immune response of the
kidney to renal ischemia/reperfusion injury,” PLoS ONE, vol.
3, no. 10, Article ID e3596, 2008.
[37] J. J. Roelofs, K. M. A. Rouschop, J. C. Leemans et al.,
“Tissue-type plasminogen activator modulates inflammatory
responses and renal function in ischemia reperfusion injury,”
Journal of the American Society of Nephrology, vol. 17, no. 1, pp.
131–140, 2006.
[38] H. Wu, G. Chen, K. R. Wyburn et al., “TLR4 activation medi-
ates kidney ischemia/reperfusion injury,” Journal of Clinical
Investigation, vol. 117, no. 10, pp. 2847–2859, 2007.
[39] L. Li, S. S. J. Sung, P. I. Lobo et al., “NKT cell activation
mediates neutrophil IFN-γ production and renal eschemia-
reperfusion injury,” Journal of Immunology, vol. 178, no. 9, pp.
5899–5911, 2007.
[40] M. Al-Maghrebi, I. F. Benter, and D. I. Diz, “Endogenous
angiotensin-(1–7) reduces cardiac ischemia-induced dysfunc-
tion in diabetic hypertensive rats,” Pharmacological Research,
vol. 59, no. 4, pp. 263–268, 2009.
[41] R. W. Schrier, W. Wang, B. Poole, and A. Mitra, “Acute renal
failure: definitions, diagnosis, pathogenesis, and therapy,”
Journal of Clinical Investigation, vol. 114, no. 1, pp. 5–14, 2004.
[42] L. Zhou, X. Yao, and Y. Chen, “Dexamethasone pretreatment
attenuates lung and kidney injury in cholestatic rats induced
by hepatic ischemia/reperfusion,” Inflammation. In press.
[43] D. N. Grigoryev, M. Liu, H. T. Hassoun, C. Cheadle, K. C.
Barnes, and H. Rabb, “The local and systemic inflammatory
transcriptome after acute kidney injury,” Journal of the Ameri-
can Society of Nephrology, vol. 19, no. 3, pp. 547–558, 2008.
8 International Journal of Hypertension
[44] D. G. Souza, S. F. Coutinho, M. R. Silveira, D. C. Cara, and
M. M. Teixeira, “Effects of a BLT receptor antagonist on local
and remote reperfusion injuries after transient ischemia of
the superior mesenteric artery in rats,” European Journal of
Pharmacology, vol. 403, no. 1-2, pp. 121–128, 2000.
[45] K. D. Silveira, F. M. Coelho, A. T. Vieira et al., “Anti-
inflammatory effects of the Activation of the angiotensin-(1–
7) receptor, mas, in experimental models of arthritis,” Journal
of Immunology, vol. 185, no. 9, pp. 5569–5576, 2010.
